Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data


Michael Blaha, MD, discusses the efficacy and safety of novel targeted therapies for lowering LDL cholesterol and emphasizes the importance of long-term data in building patient confidence in this new treatment option.

Related Videos
Video 2 - "COPD Traits Associated with Phenotypes"
Video 1 - "Why is COPD Important?"
A panel of 4 experts on HIV
A panel of 4 experts on HIV
HCPLive Five at APA 2024 | Image Credit: HCPLive
Video 4 - "Moderate/Severe/Uncontrolled Asthma Classification"
Video 3 - "Type 2 Inflammation and Biomarkers in Asthma"
© 2024 MJH Life Sciences

All rights reserved.